NanoBio Corp. Closes Series B Funding Round
Company Reaches Its $22M Funding from Multiple Investor; Plans to Enter Several Clinical and Pre-Clinical Trials for Product Development
July 9, 2009
According to the company’s release, “’This investment round secures our ability to independently fund the next two years of our operations,” commented James R. Baker, Jr., MD, NanoBio’s CEO and founder.’” Funders for the Series B round include Perseus LLC and Venture Investors. NanoBio Corp. is a biopharmaceutical company developing dermatological products, anti-infective treatments and intranasal vaccines. The company’s dermatology and anti-infective product candidates include treatments for cold sores, onychomycosis (nail fungus), acne, and cystic fibrosis.
